Media Center
Catch up on the latest Johnson & Johnson news and download the J&J logo and media assets here.
At Johnson & Johnson our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.
Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. We will combine our science and technology with our determination to create a powerful force of care ... and profoundly impact health for humanity.
Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. We will combine our science and technology with our determination to create a powerful force of care ... and profoundly impact health for humanity.
Highlighted press releases
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren’s disease
Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
If approved, DARZALEX FASPRO® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage
Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE™ Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation
The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy1 Approval is supported by the admIRE study, where 85% peak primary effectiveness 12-month success and minimal-to-no fluoroscopy were achieved2,i
Contact Global Media Relations
Journalists please use the following Johnson & Johnson media relations contacts for inquiries.
We recommend that if you are on deadline—or if it is after business hours—put ON DEADLINE in the subject of your email. It is also helpful if you are as specific as possible with your request.
Office Telephone: 732-524-1090
media-relations@its.jnj.com
We recommend that if you are on deadline—or if it is after business hours—put ON DEADLINE in the subject of your email. It is also helpful if you are as specific as possible with your request.
Office Telephone: 732-524-1090
media-relations@its.jnj.com
Media interviews
Johnson & Johnson has a state-of-the-art production studio available for media interviews. We have an HD-SDI fiber optic cable connection to the All Mobile Video Gateway in Weehawken, New Jersey. From All Mobile Video Gateway, we can be patched to just about anywhere in the United States accessible by fiber optic cable. Our studio can also send our signal to an AMV uplink which allows for international video connections.
All press releases
More information
Discover J&J
We are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow.
Our societal impact
We seek to provide solutions for some of the world’s most pressing global public health challenges.